Intellia Therapeutics, Inc. - Common Stock (NTLA)

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Intellia (NTLA) Q3 2025 Earnings Call Transcript

There might be plenty more downside for these biotechs.

The companies are working on one-and-done treatments for diseases tied to genetic problems.

Wall Street may be overestimating these companies' potential.

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Intellia stock plunges after FDA places clinical hold on its Phase 3 trials for lead candidate nex-z, overshadowing Q3 earnings.

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]

Maybe Cathie Wood and Wall Street are being too optimistic.

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

Intellia Therapeutics shares are tumbling in after-hours trading on Wednesday. Here's what you need to know.